Severe hemophilia A with inhibitors and pancreatic cancer - when emicizumab is not enough.
Blood transfusion · 01.01.2026 · 24 (2) · 157-159
DOI: 10.2450/bloodtransfus.1198 ↗Kurz gefasst
Fallbericht in der Zeitschrift Blood transfusion, erschienen am 01.01.2026. Verfasst von Mario Biglietto und 10 weiteren Autor:innen. Beteiligte Einrichtung: Hematology, Department of Translational and Precision Medicine Sapienza University of Rome, Italy. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Short description Since the early 2000s, FVIII prophylaxis has been the standard for severe hemophilia A, but patients with inhibitors who failed immune tolerance induction (ITI) had no effective prophylaxis until emicizumab, which significantly reduced bleeding rates and improved quality of life. A 67-year-old man with severe hemophilia A and high-titer inhibitors, managed previously with bypassing agents, began emicizumab prophylaxis in 2021 and experienced over three years without bleeding, including safe dental procedures. In 2024, he was diagnosed with stage III pancreatic cancer, and despite emicizumab, he had multiple severe bleeding episodes during diagnostic and therapeutic procedures, requiring large doses of rFVIIa; bleeding ceased after stereotactic radiotherapy. This case highlights emicizumab’s transformative impact but also its limitations during major medical interventions, emphasizing the continued need for on-demand treatment and consideration of ITI even in the era of non-factor therapies.
Schlagwörter
Autor:innen und Institutionen
- Hematology, Department of Translational and Precision Medicine Sapienza University of Rome, Italy.
- Center for Bleeding Disorders and Coagulation, Department of Oncology, Careggi University Hospital, Florence, Italy.
Zitieren
APA
Biglietto, M., Linari, S., Faccini, A. L., Sorella, S., Crisanti, E., Antonacci, M., Ligia, S., Mormile, R., Ciciani, R., Baldacci, E., & Santoro, C. (2026). Severe hemophilia A with inhibitors and pancreatic cancer - when emicizumab is not enough. Blood transfusion, 24(2), 157-159. https://doi.org/10.2450/bloodtransfus.1198
Vancouver
Biglietto M, Linari S, Faccini AL, Sorella S, Crisanti E, Antonacci M, et al. Severe hemophilia A with inhibitors and pancreatic cancer - when emicizumab is not enough. Blood transfusion. 2026;24(2):157-159. doi:10.2450/bloodtransfus.1198
BibTeX
@article{Biglietto2026,
author = {Biglietto, Mario and Linari, Silvia and Faccini, Anna Laura and Sorella, Silvia and Crisanti, Erica and Antonacci, Marco and Ligia, Silvio and Mormile, Rosaria and Ciciani, Roberta and Baldacci, Erminia and Santoro, Cristina},
title = {Severe hemophilia A with inhibitors and pancreatic cancer - when emicizumab is not enough},
journal = {Blood transfusion},
year = {2026},
volume = {24},
number = {2},
pages = {157--159},
doi = {10.2450/bloodtransfus.1198}
}
EUVIMED